How to buy Intec Pharma stock

Intec Pharma Ltd is a biotechnology business based in the US. Intec Pharma shares (NTEC) are listed on the NASDAQ and all prices are listed in US Dollars. Intec Pharma employs 38 staff and has a market cap (total outstanding shares value) of 0.00.

Intec Pharma share price

Use our graph to track the performance of NTEC stocks over time.

Intec Pharma shares at a glance

• Key figures

Information last updated 2021-03-10.

52-week range	$2.20 - $11.20
50-day moving average	$4.93
200-day moving average	$4.48
Wall St. target price	$9.00
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-1.28

Buy Intec Pharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Intec Pharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Intec Pharma Ltd by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Intec Pharma financials

Gross profit TTM	$0
Return on assets TTM	-28.25%
Return on equity TTM	-96.24%
Profit margin	0%
Book value	$4.58
Market capitalisation	$17 million

TTM: trailing 12 months

Shorting Intec Pharma shares

There are currently 545,490 Intec Pharma shares held short by investors – that's known as Intec Pharma's "short interest". This figure is 5.5% up from 517,065 last month.

There are a few different ways that this level of interest in shorting Intec Pharma shares can be evaluated.

Intec Pharma's "short interest ratio" (SIR)

Intec Pharma's "short interest ratio" (SIR) is the quantity of Intec Pharma shares currently shorted divided by the average quantity of Intec Pharma shares traded daily (recently around 1.3 million). Intec Pharma's SIR currently stands at 0.41. In other words for every 100,000 Intec Pharma shares traded daily on the market, roughly 410 shares are currently held short.

However Intec Pharma's short interest can also be evaluated against the total number of Intec Pharma shares, or, against the total number of tradable Intec Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Intec Pharma's short interest could be expressed as 0.13% of the outstanding shares (for every 100,000 Intec Pharma shares in existence, roughly 130 shares are currently held short) or 0.1317% of the tradable shares (for every 100,000 tradable Intec Pharma shares, roughly 132 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Intec Pharma.

Find out more about how you can short Intec Pharma stock.

Intec Pharma share dividends

We're not expecting Intec Pharma to pay a dividend over the next 12 months.

Have Intec Pharma's shares ever split?

Intec Pharma's shares were split on a 1:20 basis on 29 October 2020. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Intec Pharma shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Intec Pharma shares which in turn could have impacted Intec Pharma's share price.

Intec Pharma share price volatility

Over the last 12 months, Intec Pharma's shares have ranged in value from as little as $2.2 up to $11.2. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Intec Pharma's is 1.2145. This would suggest that Intec Pharma's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Intec Pharma overview

Intec Pharma Ltd, a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. The company's lead product candidate is Accordion Pill Carbidopa/Levodopa, which is in a Phase III clinical trial for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients. It is also developing Accordion Pill Zaleplon that is in a Phase III clinical trial as a treatment for the induction and maintenance of sleep in patients suffering from insomnia; a product candidate, which has completed a Phase I clinical trial for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers; and AP-CBD/THC, AP-THC, and AP-CBD product candidates with Cannabidiol and 9-Tetrahydrocannabinol for the treatment of various pain indications. Intec Pharma Ltd. has a research collaboration agreement with Merck to explore using the Accordion Pill platform for development program; and a feasibility agreement with GW Research Limited to explore an undisclosed research program using the Accordion Pill platform. The company was formerly known as Intec Pharmaceuticals (2000) Ltd.

Frequently asked questions

• What percentage of Intec Pharma is owned by insiders or institutions?

  Currently 8.743% of Intec Pharma shares are held by insiders and 21.821% by institutions.

• How many people work for Intec Pharma?

  Latest data suggests 38 work at Intec Pharma.

• When does the fiscal year end for Intec Pharma?

  Intec Pharma's fiscal year ends in December.

• Where is Intec Pharma based?

  Intec Pharma's address is: RMPE building, Jerusalem, Israel, 9777512

• What is Intec Pharma's ISIN number?

  Intec Pharma's international securities identification number is: IL0011177958

• What is Intec Pharma's CUSIP number?

  Intec Pharma's Committee on Uniform Securities Identification Procedures number is: IL0011177